X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
ALEMBIC PHARMACEUTICALS LTD. Fact Sheet - Equitymaster
Investing in India? Get Equitymaster Research  

ALEMBIC PHARMACEUTICALS LTD.  (APLL)


Here is the latest financial fact sheet of ALEMBIC PHARMA. For more details, see the ALEMBIC PHARMA quarterly results and ALEMBIC PHARMA share price and chart. For a sector overview, read our pharmaceuticals sector report.
 
alembic pharma - 1 Year Stock Price Chart
Loading...

 Price History
    Price Rs 624.0       No. of shares m 188.52
    Mkt Cap Rs m 117,636       % ch % 2.1
    Vol '000 24.3       % ch week % 2.3
    P/E X 29.3       % ch 1-mth % 6.5
    P/CF X 14.9       % ch 12-mth % 1.3
    EPS (TTM) Rs 21.3       52 week H/L Rs 709.3/517.9
(As on Apr 26, 2017 03:23:00 PM) »  Best Performing pharmaceuticals Stocks

Excel EXPORT | DO YOU LIKE THESE FACTSHEETS? TELL US!
 Financials

* Results Consolidated
No. of Months
Year Ending
12
Mar-12
*
12
Mar-13
*
12
Mar-14
*
12
Mar-15
*
12
Mar-16
*
5-Yr Chart
Click to enlarge
  EQUITY SHARE DATA
High Rs51113310495792 
Low Rs3448103228443 
Sales per share (Unadj.) Rs77.780.698.8109.1167.0 
Earnings per share (Unadj.) Rs6.98.812.515.038.2 
Diluted earnings per shareRs6.98.812.515.038.2 
Cash flow per share (Unadj.) Rs8.710.614.617.442.0 
Dividends per share (Unadj.) Rs1.402.503.003.504.00 
Adj. dividends per shareRs1.402.503.003.504.00 
Dividend yield (eoy) %3.33.11.51.00.6 
Book value per share (Unadj.) Rs21.026.735.846.984.9 
Adj. book value per shareRs21.026.735.846.984.9 
Shares outstanding (eoy) m188.52188.52188.52188.52188.52 
Bonus/Rights/Conversions  ----- 
Price / Sales ratio x0.51.02.13.33.7 
Avg P/E ratio x6.29.116.524.116.2 
P/CF ratio (eoy) x4.97.614.120.814.7 
Price / Book Value ratio x2.03.05.87.77.3 
Dividend payout %20.328.524.023.310.5 
Avg Mkt Cap Rs m8,01215,11938,93968,122116,383 
No. of employees `000NANANANANA 
Total wages/salary Rs m1,6851,9382,4703,0684,214 
Avg. sales/employee Rs ThNMNMNMNMNM 
Avg. wages/employee Rs ThNMNMNMNMNM 
Avg. net profit/employee Rs ThNMNMNMNMNM 
  INCOME DATA
Net Sales Rs m14,65415,20418,63220,56131,487 
Other income Rs m1439322355 
Total revenues Rs m14,66815,24318,66420,58431,542 
Gross profit Rs m2,1942,5203,5774,03010,060 
Depreciation Rs m337350405444722 
Interest Rs m262146981837 
Profit before tax Rs m1,6102,0643,1063,5919,356 
Minority Interest Rs m00000 
Prior Period Items Rs m0002-2 
Extraordinary Inc (Exp) Rs m00000 
Tax Rs m3094117517642,160 
Profit after tax Rs m1,3011,6532,3552,8297,194 
Gross profit margin %15.016.619.219.631.9 
Effective tax rate %19.219.924.221.323.1 
Net profit margin %8.910.912.613.822.8 
  BALANCE SHEET DATA
Current assets Rs m6,8766,3227,0158,90715,066 
Current liabilities Rs m5,3494,4164,4746,8417,674 
Net working cap to sales %10.412.513.610.123.5 
Current ratio x1.31.41.61.32.0 
Inventory Days Days6464616867 
Debtors Days Days5056546441 
Net fixed assets Rs m3,2613,7654,1765,9478,237 
Share capital Rs m377377377377377 
"Free" reserves Rs m3,2034,5826,2358,37415,416 
Net worth Rs m3,9505,0296,7568,84616,005 
Long term debt Rs m9497055221880 
Total assets Rs m10,51910,47812,17316,41224,594 
Interest coverage x7.115.232.7202.7255.2 
Debt to equity ratio x0.20.10.100 
Sales to assets ratio x1.41.51.51.31.3 
Return on assets %14.917.220.217.329.4 
Return on equity %32.932.934.932.044.9 
Return on capital %38.238.544.040.058.7 
Exports to sales %31.930.640.339.355.7 
Imports to sales %12.510.29.510.010.4 
Exports (fob) Rs m4,6804,6507,5028,08517,551 
Imports (cif) Rs m1,8321,5541,7652,0503,283 
Fx inflow Rs m4,7964,8027,7208,28417,811 
Fx outflow Rs m2,2752,1992,6283,1475,318 
Net fx Rs m2,5212,6035,0925,13712,493 
  CASH FLOW
From Operations Rs m 1,418 2,648 2,400 1,718 9,304 
From Investments Rs m -564 -670 -811 -2,556 -3,105 
From Financial Activity Rs m -446 -2,288 -1,511 867 -1,959 
Net Cashflow Rs m 408 -310 79 29 4,240 
* Results Consolidated Source: Company Annual Reports, Regulatory Filings, Equitymaster »  Historical quarterly results for alembic pharmaceuticals ltd.

 Share Holding
Indian Promoters : 74.1%
Foreign collaborators : 0.0%
Indian inst/Mut Fund : 2.9%
FIIs : 9.1%
ADR/GDR : 0.0%
Free float : 13.9%
Shareholders : 49,328
Pledged promoter(s) holding : 0.0%
 Company Information
Top
    REGD OFF: Alembic Road, ,Vadodara,Gujarat - 390 003
    E-MAIL: apl.investors@alembic.co.in     WEB: www.alembic-india.com
    TELEPHONE: (0265) 2282 550     FAX: (0265) 2282 506
    SECTOR: PHARMACEUTICALS     GROUP: MISCELLANEOUS
    TR AGENT: Link Intime India, B-102-103, Shangrila Complex, Akota, Vadodara-20
    AUDITOR: K. S. Aiyar & Co.
CHM: Chirayu R. Amin (MD) COMP SEC: Rajkumar Baheti YEAR OF INC: 2010 BSE CODE: 533573 FV (Rs): 2 DIV YIELD (%): 0.6

More pharmaceuticals Company Fact Sheets:   FDC LTD.DIVIS LABORATORIESAJANTA PHARMAINDRAPRASTHA MEDICALDISHMAN PHARMA


Today's Market

Indian Indices Trade Near Record Highs; Auto Stocks Lead Gains(01:30 pm)

After opening the day on a positive note, share markets in India have continued the momentum and are trading near their record high levels.

Views on news

Sun Pharma: Slow Growth Across Major Markets (Quarterly Results Update - Detailed)

Mar 11, 2017

Sun Pharma has announced its December quarter (3QFY17) results. The company has reported 8% YoY growth in sales and a decline of 4.7% YoY in the net profits.

Cipla: Operating Margins Improve (Quarterly Results Update - Detailed)

Mar 8, 2017

Cipla has announced its results for the December quarter (1QFY17) results. The company has reported a decline of 6.4% YoY in sales while profits were down by 43.7% YoY.

Lupin: US Business Drives Growth (Quarterly Results Update - Detailed)

Mar 8, 2017

Lupin has announced its 3QFY17 results. Net sales have grown by 31.5% YoY and net profits have surged by 20.7% YoY. Here is our analysis of the results.

Glenmark: Zetia Generics Boost Growth (Quarterly Results Update - Detailed)

Feb 15, 2017

Glenmark has announced its 3QFY16 results. The company has reported 41% YoY growth in net sales and 143.2% YoY increase in net profits. Here is our analysis of the results.

Sun Pharma: USFDA Observations Post Good Quarterly Performance (Quarterly Results Update - Detailed)

Dec 12, 2016

Sun Pharma has announced its September quarter (2QFY17) results. The company has reported 13.2% YoY growth in sales and a growth of 117% in the net profits. Here is our analysis of the results.

More Views on News

Most Popular

Our Private Class with India's Value Investing Guru(The 5 Minute Wrapup)

Apr 19, 2017

Rohan and Kunal present you the discussions with professor Sanjay Bakshi in his virtual classroom.

HDFC Bank: The Solid Outperformer(Chart Of The Day)

Apr 22, 2017

Why HDFC Bank beat the Sensex by nearly 3 times.

Aur Bhi Dukh Hain Zamane Main Stock Market Ke Siva...(Vivek Kaul's Diary)

Apr 13, 2017

The link between the Indian economy and the stock market is weak, and the stock market is not a reflection of the Indian economy.

The Real Reason Indiabulls Real Estate Jumped 42%(Daily Profit Hunter)

Apr 19, 2017

An elephant and six blind men will tell you more about the markets than any financial newspaper or channel.

7 Benefits Of Creating A CAN(Outside View)

Apr 13, 2017

The MFU platform offers ease, convenience, and speed of transacting in various mutual fund schemes.

More

TRACK ALEMBIC PHARMA

  • Track your investment in ALEMBIC PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON ALEMBIC PHARMA

ALEMBIC PHARMA - ACTAVIS COMPARISON

Compare Company With Charts

COMPARE ALEMBIC PHARMA WITH

MARKET STATS